#Switzerland #Geneva #MindMaze Therapeutics #SwissNeuroRehab #Neurorehabilitation

MindMaze Therapeutics Implements SwissNeuroRehab Study

MindMaze Therapeutics Holding SA has announced a significant step forward in neurorehabilitation with the initiation of the SwissNeuroRehab study. This marks a pivotal moment in their strategy to establish at-home stroke rehabilitation solutions across Europe. Enrolment for the study has officially begun at key Swiss institutions in collaboration with approximately 100 hospitals and care facilities across the continent.

Study Overview

The SwissNeuroRehab study, which is backed by a CHF 11.2 million initiative from Innosuisse, encompasses a consortium of top Swiss university hospitals and rehabilitation centers. The goal is to assess the feasibility of a High-Dose, High-Intensity (HDHI) neurorehabilitation approach throughout various stages of patient care. This approach not only targets inpatient care but also emphasizes the transition to outpatient and home-based recovery.

The study takes a comprehensive approach to neurorehabilitation, spanning six major centers and embracing the full continuum of care. Patients will undergo a rigorous training regimen, with the study aiming for 300 minutes of active rehabilitation weekly. This regimen is intricately designed to facilitate a smooth transition from intensive inpatient care to supportive outpatient and home environments.

Recruitment and Participation

Recruitment is currently underway at prestigious locations such as the Lausanne University Hospital, Rehaklinik Valens, and the University Hospital Zurich. The clinical trial is registered on ClinicalTrials.gov under the identifier NCT07427511, facilitating transparency and easier access for potential participants and their families.

Real-World Impact

The implications of the SwissNeuroRehab study extend beyond clinical trial results. By establishing a solid foundation for home-based therapy, MindMaze aims to create a model for reimbursement that aligns with proven methodologies already applied in the United States. CEO Zach Henderson emphasized the critical need for a continuous care model, stating, "These studies reflect our commitment to making our neurotherapeutic platform accessible to patients throughout their recovery journey."

Integration with REACT-AVC Study

In conjunction with the SwissNeuroRehab initiative, MindMaze has also unveiled the REACT-AVC study at Hospices Civils de Lyon, focusing on early outpatient and home-based rehabilitation strategies for stroke patients in France. These dual studies will generate crucial clinical and health-economic data, providing a comprehensive understanding of the benefits and efficacy of neurorehabilitation in various healthcare contexts.

Together, the SwissNeuroRehab and REACT-AVC studies represent a strategic, coordinated effort by MindMaze Therapeutics to gather substantial evidence around the clinical and economic value of neurorehabilitation at home.

Future Ambitions

MindMaze's ambitions stretch beyond Swiss and French borders, with active involvement in the Neurorehab4EU project, a European consortium targeting the implementation of scalable software-enabled neurorehabilitation across healthcare systems. This initiative embodies MindMaze’s commitment to changing the landscape of post-stroke recovery, ultimately improving patient outcomes and integrating care across a comprehensive system.

Conclusion

As MindMaze Therapeutics steps forward with both the Swiss and French studies, it sets the stage for a transformative shift in at-home stroke rehabilitation. By providing access to innovative care pathways, the company aims to redefine recovery options for patients while establishing a sustainable framework for reimbursement and care quality in Europe. Stay tuned as further updates emerge from these pivotal studies that are sure to shape the future of neurorehabilitation across the continent.